These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37373883)

  • 21. Cost-effectiveness of diagnostic testing strategies including cervical-length measurement and fibronectin testing in women with symptoms of preterm labor.
    van Baaren GJ; Vis JY; Wilms FF; Oudijk MA; Kwee A; Porath MM; Scheepers HCJ; Spaanderman MEA; Bloemenkamp KWM; Haak MC; Bax CJ; Cornette JMJ; Duvekot JJ; Nij Bijvanck BWA; van Eyck J; Franssen MTM; Sollie KM; Vandenbussche FPHA; Woiski M; Bolte AC; van der Post JAM; Bossuyt PMM; Opmeer BC; Mol BWJ
    Ultrasound Obstet Gynecol; 2018 May; 51(5):596-603. PubMed ID: 28370518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the quantitative fetal fibronectin test and PAMG-1 test for the prediction of spontaneous preterm birth in patients with signs and symptoms suggestive of preterm labor.
    Ravi M; Beljorie M; El Masry K
    J Matern Fetal Neonatal Med; 2019 Dec; 32(23):3909-3914. PubMed ID: 29807458
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of fibronectin testing in a triage in women with threatened preterm labor: alleviation of pregnancy outcome by suspending tocolysis in early labor (APOSTEL-I trial).
    Vis JY; Wilms FF; Oudijk MA; Porath MM; Scheepers HC; Bloemenkamp KW; Bolte AC; Cornette J; Derks JB; Duvekot JJ; van Eyck J; Kwee A; Opmeer BC; van Pampus MG; Lotgering FK; Scherjon SA; Sollie KM; Spaanderman ME; Willekes C; van der Post JA; Mol BW
    BMC Pregnancy Childbirth; 2009 Sep; 9():38. PubMed ID: 19723320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the effectiveness of foetal fibronectin as a predictor of preterm birth in symptomatic preterm labour women.
    Jun SY; Lee JY; Kim HM; Kim MJ; Cha HH; Seong WJ
    BMC Pregnancy Childbirth; 2019 Jul; 19(1):241. PubMed ID: 31296172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of cervical gland area in predicting preterm birth for patients with threatened preterm delivery: comparison with cervical length and fetal fibronectin.
    Asakura H; Fukami T; Kurashina R; Tateyama N; Doi D; Takeshita T
    Gynecol Obstet Invest; 2009; 68(1):1-8. PubMed ID: 19321961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of the quantitative fetal fibronectin levels for the management of women presenting with threatened preterm labour - A revised cut off level: A retrospective cohort study.
    Mahomed K; Ibiebele I; Fraser C; Brown C
    Eur J Obstet Gynecol Reprod Biol X; 2019 Oct; 4():100079. PubMed ID: 31508583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical utility of fetal fibronectin in the prediction of pre-term birth in a low socio-economic setting hospital in Ecuador.
    Díaz J; Chedraui P; Hidalgo L; Medina M
    J Matern Fetal Neonatal Med; 2009 Feb; 22(2):89-93. PubMed ID: 19085632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Presence of fetal fibronectin in cervico-vaginal secretion as predictor of premature labor].
    García Alonso A; Ayala Méndez JA; Izquierdo Puente JC; Jiménez Solís G; Sánchez Martínez M
    Ginecol Obstet Mex; 1999 Jan; 67():23-8. PubMed ID: 10085606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a novel test for placental alpha microglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor.
    Nikolova T; Bayev O; Nikolova N; Di Renzo GC
    J Perinat Med; 2015 Jul; 43(4):395-402. PubMed ID: 25562603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fetal fibronectin testing for reducing the risk of preterm birth.
    Berghella V; Hayes E; Visintine J; Baxter JK
    Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD006843. PubMed ID: 18843732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of cervical length measurement and fibronectin testing in women with threatened preterm labor.
    van Baaren GJ; Vis JY; Grobman WA; Bossuyt PM; Opmeer BC; Mol BW
    Am J Obstet Gynecol; 2013 Nov; 209(5):436.e1-8. PubMed ID: 23791688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of rapid bedside tests for phosphorylated insulin-like growth factor-binding protein 1 and fetal fibronectin to predict preterm birth.
    Tripathi R; Tyagi S; Mala YM; Singh N; Pandey NB; Yadav P
    Int J Gynaecol Obstet; 2016 Oct; 135(1):47-50. PubMed ID: 27388033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of fetal fibronectin testing for women with symptoms of preterm labour in routine clinical practice within a New Zealand population.
    Groom KM; Liu E; Allenby K
    Aust N Z J Obstet Gynaecol; 2006 Oct; 46(5):440-5. PubMed ID: 16953860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of cervicovaginal fetal fibronectin in a community hospital setting.
    Incerti M; Ghidini A; Korker V; Pezzullo JC
    Arch Gynecol Obstet; 2007 May; 275(5):347-51. PubMed ID: 17051404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic value of fetal fibronectin testing in clinical practice.
    Cornelissen LGH; van Oostrum NHM; van der Woude DAA; Rolf C; Porath MM; Oei SG; van Laar JOEH
    J Obstet Gynaecol Res; 2020 Mar; 46(3):405-412. PubMed ID: 31955485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings.
    Giles W; Bisits A; Knox M; Madsen G; Smith R
    Am J Obstet Gynecol; 2000 Feb; 182(2):439-42. PubMed ID: 10694349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-Policy Implementation Review of Rapid Fetal Fibronectin (fFN) Testing for Preterm Labour in Alberta.
    Chuck AW; Thanh NX; Chari RS; Wilson RD; Janes-Kelley S; Wesenberg JC
    J Obstet Gynaecol Can; 2016 Jul; 38(7):659-666.e6. PubMed ID: 27591351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fetal fibronectin testing and pregnancy outcomes among Texas Medicaid patients at risk for preterm birth.
    Barner JC; Petrilla AA; Kang HA; Shen X; Alshehri AM; Sullivan EM; Troeger KA; Richards KM; Blackwell SC
    Am J Manag Care; 2017 Dec; 23(19 Suppl):S363-S370. PubMed ID: 29297659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the impact of fetal fibronectin test implementation on hospital admissions for preterm labour in Ontario: a multiple baseline time-series design.
    Fell DB; Sprague AE; Grimshaw JM; Yasseen AS; Coyle D; Dunn SI; Perkins SL; Peterson WE; Johnson M; Bunting PS; Walker MC
    BJOG; 2014 Mar; 121(4):438-46. PubMed ID: 24289187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of quantitative fetal fibronectin for the prediction of preterm birth in women with exposed fetal membranes undergoing emergency cervical cerclage.
    Suff N; Hall M; Shennan A; Chandiramani M
    Eur J Obstet Gynecol Reprod Biol; 2020 Mar; 246():19-22. PubMed ID: 31923878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.